Trial Profile
Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Pyrotinib as a Single Agent in HER2 Mutation Advanced Non-small Cell Lung Cancer Patients Who Failed to Previous at Least 2nd Line Treatments
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pyrotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Sep 2015 New trial record